X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 99% Over Last Week

Simply Wall StDec 12 19:26

X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

X4 PharmicalsDec 4 13:00

Express News | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 4 05:05

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 PharmicalsDec 3 13:00

B.Riley Financial Maintains X4 Pharmaceuticals(XFOR.US) With Hold Rating, Cuts Target Price to $0.5

Futu NewsNov 19 16:36 · Ratings

B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating

MT NewswiresNov 18 22:01 · Ratings